Rat sarcoma (RAS) oncogenes, such as KRAS and NRAS, with driver mutations, portend poor survival outcomes, whereas pathologic mutations in HRAS are extremely rare, and their prognostic value remains uncertain.<h4>Methods</h4>This retrospective study analyzed the Oncology Research Information Exchange Network (ORIEN) alliance tumor RNA-Seq data in Stages II and III CRC to investigate the association between RAS gene expression and survival outcomes.<h4>Results</h4>High transcript levels of HRAS were associated with superior overall survival (OS). The gene discussed is NRAS; the disease is colorectal carcinoma.